羅氏GS Junior測(cè)序系統(tǒng)用于腫瘤個(gè)人化治療研究

瀏覽次數(shù)：3435　發(fā)布日期：2012-2-7　來源：本站　本站原創(chuàng)，轉(zhuǎn)載請(qǐng)注明出處

羅氏GS Junior測(cè)序系統(tǒng)用于腫瘤個(gè)人化治療研究

腫瘤個(gè)人化治療成功與否很大程度上取決于其腫瘤基因的突變類型。在德國(guó)一個(gè)實(shí)驗(yàn)室中，羅氏GS Junior測(cè)序系統(tǒng)被用于腫瘤個(gè)人化治療研究中，通過對(duì)臨床治療相關(guān)的外顯子DNA進(jìn)行測(cè)序，鑒定腫瘤組織的基因組突變類型，為后續(xù)的抗體治療藥物提供用藥指導(dǎo)。

The next-generation GS Junior Sequencing System enables cost effective and comprehensive profiling of all the relevant genes.

腫瘤個(gè)人化治療是腫瘤治療的發(fā)展方向，比如使用單克隆抗體，抑制一些蛋白的促腫瘤生長(zhǎng)作用。全面而準(zhǔn)確評(píng)估患者的腫瘤基因背景，是抗體治療成功的關(guān)鍵。目前這種治療只針對(duì)少數(shù)的腫瘤相關(guān)基因區(qū)域，而使用二代測(cè)序儀GS Junior系統(tǒng)能夠經(jīng)濟(jì)、有效地獲得所有這些相關(guān)基因的序列信息。與此相比，傳統(tǒng)毛細(xì)管電泳測(cè)序方法，檢測(cè)靈敏度較低，價(jià)格相對(duì)較高，尤其是對(duì)于腫瘤突變小于20%的情況。

二代測(cè)序技術(shù)將對(duì)腫瘤個(gè)人化治療起到重要作用。GS Junior能夠獲得腫瘤組織的混合細(xì)胞中各種基因突變信息，無論是已知的還是新型的突變。此外，GS Junior在分析復(fù)雜的腫瘤樣本方面的優(yōu)勢(shì)在于它的長(zhǎng)讀長(zhǎng)特點(diǎn)，在可以靈敏檢測(cè)低頻率的體細(xì)胞突變的同時(shí)，又可以判定各種類型的腫瘤突變，包括大片段的結(jié)構(gòu)變異。

Roche´s GS Junior Sequencing System used in research on personalized tumor treatment

Individual tumor treatment success largely depends on the mutation status of tumor genes. Roche’s GS Junior Sequencing system is now used for a sequencing approach that has great potential for personalized medicine: the Center for Human Genetics and Laboratory Medicine Dr. Klein and Dr. Rost, and IMGM Laboratories, both located in Martinsried, Germany, reported using the Roche GS Junior Benchtop System to sequence clinically relevant protein coding DNA (exons) and identify genomic variations in solid tumors treated with an antibody-based medicine.

Personalized tumor treatments, such as monoclonal antibodies (mAb) that specifically target tumor-inducing proteins, require a precise and comprehensive assessment of an individual’s genetic profile for the targeted genes. Current therapies target only a limited region of the relevant tumor genes, whereas the next-generation GS Junior Sequencing System enables cost effective and comprehensive profiling of all the relevant genes. In contrast, conventional capillary sequencing techniques often lack the sensitivity and cost effectiveness to detect tumor mutations occurring at less than 20 percent frequency.

“The future of personalized tumor treatment lies in this sequencing approach,” said Dr. Hanns-Georg Klein, MD, CEO of both IMGM and the Center for Human Genetics. “Through our research, we’ve found that it’s critical to ensure a comprehensive analysis of a tumor variant population, including known and novel mutations.”

These findings underscore the utility of Roche’s GS Junior System for investigating complex tumor samples. The long, accurate sequencing reads are ideal for identifying multiple tumor mutations that can include structural variations and rare somatic mutations.

【點(diǎn)擊可查看羅氏診斷產(chǎn)品（上海）有限公司相關(guān)產(chǎn)品】

分享到：QQ空間新浪微博騰訊微博微信

【所有新聞】【本類新聞】【相關(guān)產(chǎn)品】【關(guān)閉窗口】

相關(guān)鏈接

本類新聞

關(guān)于我們 | 法律聲明 | 廣告報(bào)價(jià) | English | 網(wǎng)站地圖